TGFB1 and neoplasm: Tregs enhance tumor invasiveness through Foxp3-dependent epigenetic reprogramming (42), secrete IL-10 and TGF-β to inhibit CD8+ T cell cytotoxicity (43), and downregulate costimulatory molecules, hindering effective T cell activation.